Here is the full press release
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose
For the non-Relvyrio participants in the trial they reported :
a 22% improvement in slope of change in ALSFRS-R assessment adjusted for mortality, with an 89% success probability, at 24 weeks
the rate of decline in ALSFRS-R slope (points per month) also favoured the SLS-005 treatment group versus placebo over 6 months (-0.80 and -1.07 points per month, respectively)
A couple of things stand out to me in these results for this subgroup :
- adjusted for mortality .... say no more !
- the rate of -.8 decline for those on SLS-005 vs -1.07 for those on placebo.
MPL ( 12 patients only )
- no mortality
- rate of decline on 10mg ( cohort 2 - 6 patients ), -.6 decline, 58% slower decline
To put it bluntly ... we win !
Here is the full press releaseSeelos Therapeutics Provides...
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $98.49M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.0¢ | $51.92K | 254.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 91550 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 461092 | 8 |
View Market Depth
| Last trade - 12.40pm 27/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |